ASSESSMENT OF RECOMBINANT ZOSTER VACCINE SECOND-DOSE COMPLETION IN THE UNITED STATES

B J Patterson, C-C Chen, C B McGuiness, L I Glasser, K Sun, P O Buck

1GSK, Philadelphia, PA, USA, 2IQVIA, Plymouth Meeting, PA, USA, *Presenting author: Brandon Patterson - brandon.j.patterson@gsk.com

OBJECTIVES

- Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥50 years of age (YOA).1
- The vaccine is administered in a two-dose series with the 2nd dose recommended between 2-6 months after initial dose.1
- This study describes 2nd dose completion of RZV in the US within 6 and 12 months of initial dose.

METHODS

- Primary analysis was conducted on a cohort ≥50 YOA who received an initial RZV dose between October 2017 and September 2018 and had ≥1 year observation post initial dose.
- All eligible subjects regardless of the observable time were described in a sensitivity analysis.
- Monthly, 6-month cumulative and 12-month cumulative, 2nd dose completion with stratifications by age, sex, claim source and payer type was described.

RESULTS

RZV completion by 6 and 12 months

- 6-month completion rate: 70%
- 12-month completion rate: 82%

Subject demographics

- 50-59Y: 15.5%
- 60-64Y: 15.5%
- 65-69Y: 12.6%
- 70-79Y: 24.6%
- 80+Y: 15.5%

SEX
- MALE: 49.9%
- FEMALE: 50.1%

PAYER TYPE
- COMMERCIAL: 48.1%
- MEDICARE: 49.9%
- MEDICAL: 11.6%
- CASH: 1.7%

CLAIM SOURCE
- PHRAMACY: 88.4%
- MEDICAL: 11.6%

CONCLUSIONS

- Assessment of RZV vaccination suggests high levels of completion across age, sex, payer type and claim sources by Month 6 post initial dose increasing further by Month 12. Sensitivity analyses were consistent with primary sample analyses.
- Significantly less completion was found in Medicaid patients and settings where vaccination claims are processed outside of the vaccine recipient’s pharmacy benefit.

Funding: GlaxoSmithKline Biologicals SA (GSK study identifier: HO-18-19056)

Completion of the RZV series was shown to be 76% at 6 months and 82% at 12 months after initial dose.